1. Research Methodology
2. Executive Summary
3. Strategic Recommendation
4. Surgical Masks Product Outlook
5. Global Prader-Willi Syndrome Market: Growth and Forecast
5.1 By Value (2017-2018)
Table 1: Global Prader-Willi Syndrome Market Size, By Value, 2017-2018 (USD Million)
5.2 By Value (2019-2024)
Table 2: Global Prader-Willi Syndrome Market Size, By Value, 2019F-2024F (USD Million)
Table 3: Global Genotropin Sales, 2014-2014
Table 4: Global Norditropin Sales, 2014-2014
Table 5: Causes of Mortality in PWS Patients
Table 6: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
Table 7: Expected Global Medical Spending in 2020, By Region, (% of Total)
Table 8: Global Life Expectancy At Birth For Selected Periods
Table 9: Life Expectancy at Birth For Selected Periods, By Region
Table 10: Projected global population (In Billions)
Table 11: Projected global population aged 60 years & above (In Billions)
Table 12: GDP Per Capita PPP, By Select Countries, 2022F (USD)
Table 13: Healthcare Expenditure (Share of GDP), By Select Country, 2013-2018 (In %)
Table 14: Global Expected Healthcare Industry Outlook
Table 15: Regional Expected Healthcare Industry Growth Rate By Year 2020
Table A: Somatropin Biosimilars For GHD and PWS
Table B: Genetic Therapies In Development For Prader-Willi Syndrome
Table C: Hyperphagia / Obesity Drugs In Development For Prader-Willi Syndrome
Table D: Behavior and Appetite Drugs In Development For Prader-Willi Syndrome
Table E: Muscle Development Therapies In Development For Prader-Willi Syndrome
Table F: PWS Mean Age Of Death, By Cause
Table G: Rare Disease Definitions Across Geographic Regions
6. Global Prader-Willi Syndrome Pipeline Analysis
6.1 DCCR Pipeline Analysis
Table 16: DCCR, Clinical Study Status
Table 17: DCCR, Estimated US Market Value, According to Price and Penetration Rate, In USD Million
Table 18: DCCR, Mean US Market Value, By Price and Penetration Rate, In USD Million
Table H: DCCR, Trail Details
Table I: DCCR, US Market Analysis
6.2 Levolitide Pipeline Analysis
Table 19: Livoletide, Clinical Study Status
Table 20: Livoletide, Estimated US Market Value, In USD Million
Table 21: Livoletide, Estimated US Cost Per Patient Annually, In USD Million
Table J: Livoletide, Trail Details
Table K: Livoletide, US Market Analysis
6.3 Tesomet Pipeline Analysis
Table 22: Tesomet, Clinical Study Status
Table 23: Tesomet Timeline For PWS
Table 24: Tesomet, US Expected Sales
Table 25: Tesomet, US Expected Sales
Table L: Tesomet Trail Details
Table M: Tesomet, US Market Analysis
Table N: Tesomet, EU Market Analysis
7. Global Prader-Willi Syndrome Market, By Region
Table 26: Global Prader-Willi Syndrome Market Size, By Region, 2018, (%)
Table 27: Global Prader-Willi Syndrome Market Size, By Region, 2024, (%)
8. U.S.A Prader-Willi Syndrome Market
8.1 U.S.A Prader-Willi Syndrome Market Size (2017-2024F)
Table 28: USA Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
8.2 U.S.A Prader-Willi Syndrome Prevalence (2017-2024F)
Table 29: USA Prader-Willi Syndrome Prevalence, 2017-2024E
Table 30: Mean Total Care Costs of Patients with PWS and Matched Controls
Table 31:PWA (USA) Funds Split
Table 32: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
Table 33: Medical and Healthcare Research & Development Spending, 2013-2018 (In USD Billion)
Table 34: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
Table O: Unites States, Hospitals Related Statistics, In 2018
Table P: Unites States, Number of Leading Drug Stores, In 2017
9. Europe Prader-Willi Syndrome Market
9.1 Europe Prader-Willi Syndrome Market Size (2017-2024F)
Table 35: Europe Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
9.2 Europe Prader-Willi Syndrome Prevalence (2017-2024F)
Table 36: Europe Prader-Willi Syndrome Prevalence, 2017-2024E
Table 37: Europe Union, Proportion of population aged 65 and over, 2014-2018 (% of Total Population)
Table 38: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
Table 39: GDP (Current USD), Europe Region, By Select Country, 2014-2018 (In Trillion USD)
Table 40: Germany, Federal Government R&D Spending, 2017
Table 41: Germany, Government R&D Spending on Health Research and Industry, (Euro Million), 2017
Table 42: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
Table 43: France, Health Infrastructure, 2017
Table 44: France, Healthcare Infrastructure Related Statistics
Table 45: France, Spending on Healthcare, 2015 & 2040,(USD Per Person)
Table 46: U.K, Health Expenditure, (% of GDP), 2014-2017 (USD)
Table 47: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
Table Q: Europe, Availability of Somatropin, By Country
Table R: EU-5 Socio-Economical Statistics, 2018
Table S: Germany, Hospitals Relates Statistics, 2017
Table T: Germany, Number of leading drug store chain, 2018
Table U: Germany, Pharmacies Related Statistics, 2017
10. Japan Prader-Willi Syndrome Market
10.1 Japan Prader-Willi Syndrome Market Size (2017-2024F)
Table 48: Japan Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
10.2 Japan Prader-Willi Syndrome Prevalence (2017-2024F)
Table 49: Japan Prader-Willi Syndrome Prevalence, 2017-2024E
Table 50: Japan Healthcare Expenditure Outlook (%)
Table 51: Japan, Population, 2014-2017
Table 52: Japan, GDP Growth Per Year, 2015-2019F (In %)
Table 53: Japan, Population ages 65 and above, 2012-2018 (% of total)
Table 54: Japan, GDP Growth Per Year, 2015-2019F (In %)
Table 55: Japan, Population ages 65 and above, 2012-2018 (% of total)
Table V: Japan Healthcare System Outlook, 2017
11. Global Prader-Willi Syndrome Market - Competitive Landscape
Table W: Competitive Landscape of Selected Drugs In Development
12. Global Prader-Willi Syndrome Market - Product Benchmarking
Table X: Human Growth Hormone Products For PWS, By Company
13. Global Prader-Willi Syndrome Market: Market Dynamics
13.1 Global Prader-Willi Syndrome Market Drivers
13.2 Global Prader-Willi Syndrome Market Restrains
13.3 Global Prader-Willi Syndrome Market Trends
14. Porter Five Force Analysis
15. SWOT Analysis
16. Global Prader-Willi Syndrome Market: Regulatory Frameworks
17. Company Profiles
17.1 Pfizer
Table 56: Pfizer, Net Sales, 2014-2018 (USD Million)
Table 57: Pfizer, Revenue, By Segments, 2018 (%)
Table 58: Pfizer, Revenue, By Region, 2018 (%)
17.2 Novartis AG
Table 59: Novartis, Net Sales, 2013-2017 (USD Million)
Table 60: Novartis, Revenue, By Segment, 2018(%)
Table 61: Novartis, Revenue, By Region, 2018(%)
17.3 Novo Nordisk
Table 62: Novo Nordisk, Net Sales, 2014-2018 (In Million USD)
Table 63: Novo Nordisk, Net Sales, By Business Sector, 2018 (In %)
Table 64: Novo Nordisk, Net Sales, By Geographic Region, 2018 (In %)
17.4 Soleno Therapeutics
Table 65: Saniona, Net Sales, 2014-2018 (In Million USD)
Table 66: Saniona, Drugs in Development, 2018
17.5 Saniona